Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Registration Number
- NCT02230982
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
UNIFESP Departamento de Medicina de Pneumologia
🇧🇷Sao Paulo - SP, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital das Clínicas de Sao Paulo - INCOR
🇧🇷Sao Paulo, Brazil
H.C.da Fac. de Medicina de Ribeirao Preto
🇧🇷Ribeirao Preto, Brazil
CLARE - Clinica de Pneumologia
🇧🇷Goiania, Brazil
Centro Medico Santa Maria
🇧🇷Barra Mansa, Brazil
Universidade do Estado do Rio de Janeiro
🇧🇷Rio De Janerio, Brazil
Hospital Ana Nery
🇧🇷Salvador, Brazil